Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2012 - 2026)
Agios Pharmaceuticals (AGIO) reported Income from Continuing Operations of 99230000.0 for Q1 2026, down 9.6% on a YoY basis from 109762292.13 in Q1 2025, and up 8.15% quarter-over-quarter from 108039000.0 in Q4 2025.
Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals has reported Income from Continuing Operations for 15 years, with the latest figure at 99230000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 9.6% year-over-year to 99230000.0; the trailing twelve-month figure through Mar 2026 stood at 423245000.0 (down 163.82% YoY), and the FY2025 full-year result was 412781000.0, down 161.27% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 99230000.0, up from 108039000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 947915000.0 in Q3 2024, with the low at 112543000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 33809470.59 across 5 years, with a median of 95847000.0 in 2022.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 1137.97% — and 2025, when it sank 110.91%.
- Agios Pharmaceuticals' Income from Continuing Operations stood at 92684000.0 in 2022, then retreated by 3.51% to 95940000.0 in 2023, then retreated by 0.61% to 96523000.0 in 2024, then dropped by 11.93% to 108039000.0 in 2025, then rose by 8.15% to 99230000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 99230000.0 (Q1 2026), 108039000.0 (Q4 2025), and 103433000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn | -99.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99.23 Mn |
| Dec 31, 2025 | -108.04 Mn |
| Sep 30, 2025 | -103.43 Mn |
| Jun 30, 2025 | -112.54 Mn |
| Mar 31, 2025 | -90.54 Mn |
| Dec 31, 2024 | -96.52 Mn |
| Sep 30, 2024 | 947.92 Mn |
| Jun 30, 2024 | -97.70 Mn |
| Mar 31, 2024 | -83.18 Mn |
| Dec 31, 2023 | -95.94 Mn |
| Sep 30, 2023 | -91.32 Mn |
| Jun 30, 2023 | -85.45 Mn |
| Mar 31, 2023 | -82.52 Mn |
| Dec 31, 2022 | -92.68 Mn |
| Sep 30, 2022 | -87.27 Mn |
| Jun 30, 2022 | -95.85 Mn |
| Mar 31, 2022 | -100.45 Mn |
| Dec 31, 2021 | -98.58 Mn |
| Sep 30, 2021 | -84.26 Mn |
| Jun 30, 2021 | -82.79 Mn |